Hmgn2 - high mobility group nucleosomal binding domain 2

Predicted to enable chromatin binding activity. Acts upstream of or within negative regulation of transcription by RNA polymerase II and regulation of development, heterochronic. Located in nucleus. Is expressed in several structures, including central nervous system; eye; genitourinary system; heart; and lung. Used to study Axenfeld-Rieger syndrome type 1. Orthologous to human HMGN2 (high mobility group nucleosomal binding domain 2). [provided by Alliance of Genome Resources, Apr 2022]